Use of Dopamine Antagonists in Treatment of Migraine

被引:51
|
作者
Marmura, Michael J. [1 ]
机构
[1] Thomas Jefferson Univ, Dept Neurol, Jefferson Headache Ctr, Philadelphia, PA 19107 USA
关键词
Dopamine; Migraine; Treatment; Prophylaxis; Neuroleptics; Dopamine antagonists; Status migrainosus; Prodrome; Adverse events; Efficacy; Nausea; RANDOMIZED CLINICAL-TRIAL; CHRONIC DAILY HEADACHE; DOUBLE-BLIND TRIAL; INTRAVENOUS PROCHLORPERAZINE; METOCLOPRAMIDE; KETOROLAC; HALOPERIDOL; ASSOCIATION; FLUNARIZINE; DOMPERIDONE;
D O I
10.1007/s11940-011-0150-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Dopamine antagonists are indicated for treatment of nausea or psychosis and have an established role in the treatment of migraine. Neuroleptics, including antipsychotics, act as antagonists at the dopamine D2 receptor type. These medications also have variable activity as antihistamines and anticholinergics, and they block alpha-adrenergic and some serotonin receptor types, but their actions on dopamine are likely the reason for their efficacy in treating nausea, psychosis, and acute migraine. Neuroleptics are first-line agents in the emergency room setting for migraine, especially for patients with nausea and vomiting. In the setting of a clear prodrome, antiemetics may prevent migraine when taken before an attack. They are also indicated in clinical situations such as patients who are pregnant or have contraindications to migraine-specificmedications or NSAIDs. Recent developments suggest that dopamine is particularly important in chronic pain, and we most commonly use neuroleptic medications in the treatment of status migrainosus or medication-overuse headache. Clinicians may avoid dopamine antagonists because of unfamiliarity and a lack of large, controlled clinical trials. Their use requires special care to avoid adverse events such as sedation, akathisia or dystonic reactions, neuroleptic malignant syndrome, or movement disorders with long-term use. Some newer atypical neuroleptic agents appear promising for both acute and prophylactic migraine treatment with a lower risk of adverse events.
引用
收藏
页码:27 / 35
页数:9
相关论文
共 50 条
  • [1] Use of Dopamine Antagonists in Treatment of Migraine
    Michael J. Marmura
    [J]. Current Treatment Options in Neurology, 2012, 14 : 27 - 35
  • [2] Dopamine antagonists and migraine
    McGeeney, Brian E.
    [J]. DRUG DEVELOPMENT RESEARCH, 2007, 68 (06) : 341 - 345
  • [3] USE OF PLATELET ANTAGONISTS IN TREATMENT OF MIGRAINE
    DALESSIO, DJ
    [J]. HEADACHE, 1976, 16 (03): : 129 - 130
  • [4] Migraine headache: Rational polytherapy using dopamine antagonists
    Peroutka, SJ
    [J]. HEADACHE QUARTERLY-CURRENT TREATMENT AND RESEARCH, 1998, 9 (03): : 237 - 240
  • [5] CGRP antagonists in treatment of migraine attacks
    Kopka, Marcin
    [J]. AKTUALNOSCI NEUROLOGICZNE, 2018, 18 (02): : 99 - 102
  • [6] Relative Effectiveness of Dopamine Antagonists for Pediatric Migraine in the Emergency Department
    Sheridan, David C.
    Laurie, Amber
    Pacheco, Stephanie
    Fu, Rongwei
    Hansen, Matthew L.
    Ma, O. John
    Meckler, Garth D.
    [J]. PEDIATRIC EMERGENCY CARE, 2018, 34 (03) : 165 - 168
  • [7] CGRP antagonists in the acute treatment of migraine
    Lipton, RB
    Dodick, DW
    [J]. LANCET NEUROLOGY, 2004, 3 (06): : 332 - 332
  • [8] CGRP receptor antagonists for the treatment of migraine
    Bell, Ian M.
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [9] CGRP antagonists and antibodies for the treatment of migraine
    Vecsei, Laszlo
    Szok, Delia
    Csati, Anett
    Tajti, Janos
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (01) : 31 - 41
  • [10] Sodium channel antagonists for the treatment of migraine
    Chiossi, Lorenza
    Negro, Andrea
    Capi, Matilde
    Lionetto, Luana
    Martelletti, Paolo
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (12) : 1697 - 1706